BridgeBio Pharma, Inc. (BBIO)
BBIO Stock Price Chart
Explore BridgeBio Pharma, Inc. interactive price chart. Choose custom timeframes to analyze BBIO price movements and trends.
BBIO Company Profile
Discover essential business fundamentals and corporate details for BridgeBio Pharma, Inc. (BBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jun 2019
Employees
725.00
Website
https://www.bridgebio.comCEO
Neil Kumar
Description
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
BBIO Financial Timeline
Browse a chronological timeline of BridgeBio Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.64, while revenue estimate is $220.52m.
Earnings released on 7 May 2026
EPS came in at -$0.84 falling short of the estimated -$0.68 by -23.75%, while revenue for the quarter reached $194.52m , beating expectations by +9.24%.
Earnings released on 24 Feb 2026
EPS came in at -$1.00 falling short of the estimated -$0.71 by -40.17%, while revenue for the quarter reached $154.18m , beating expectations by +5.00%.
Earnings released on 29 Oct 2025
EPS came in at -$0.95 falling short of the estimated -$0.88 by -7.95%, while revenue for the quarter reached $120.70m , missing expectations by -18.53%.
Earnings released on 5 Aug 2025
EPS came in at -$0.95 falling short of the estimated -$0.83 by -14.46%, while revenue for the quarter reached $110.57m , beating expectations by +2.26%.
Earnings released on 29 Apr 2025
EPS came in at -$0.88 surpassing the estimated -$1.00 by +12.00%, while revenue for the quarter reached $116.63m , beating expectations by +70.48%.
Earnings released on 20 Feb 2025
EPS came in at -$1.31 falling short of the estimated -$1.09 by -20.18%, while revenue for the quarter reached $5.88m , beating expectations by +45.62%.
Earnings released on 12 Nov 2024
EPS came in at -$0.86 surpassing the estimated -$1.03 by +16.50%, while revenue for the quarter reached $2.73m , missing expectations by -95.94%.
Earnings released on 1 Aug 2024
EPS came in at -$1.02 surpassing the estimated -$1.09 by +6.42%, while revenue for the quarter reached $2.17m , missing expectations by -39.27%.
Earnings released on 2 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.40 by +87.50%, while revenue for the quarter reached $211.12m , beating expectations by +1.40k%.
Earnings released on 22 Feb 2024
EPS came in at -$0.96 falling short of the estimated -$0.95 by -1.05%, while revenue for the quarter reached $1.75m , missing expectations by -71.99%.
Earnings released on 2 Nov 2023
EPS came in at -$1.08 falling short of the estimated -$0.86 by -25.58%, while revenue for the quarter reached $4.09m , missing expectations by -3.97%.
Earnings released on 3 Aug 2023
EPS came in at -$0.98 falling short of the estimated -$0.86 by -13.95%, while revenue for the quarter reached $1.64m , missing expectations by -45.12%.
Earnings released on 4 May 2023
EPS came in at -$0.92 falling short of the estimated -$0.84 by -9.52%, while revenue for the quarter reached $1.83m , missing expectations by -45.82%.
Earnings released on 23 Feb 2023
EPS came in at -$0.87 falling short of the estimated -$0.86 by -1.16%, while revenue for the quarter reached $1.87m , missing expectations by -58.67%.
Earnings released on 3 Nov 2022
EPS came in at -$0.93 surpassing the estimated -$1.02 by +8.82%, while revenue for the quarter reached $338.00k , missing expectations by -91.73%.
Earnings released on 4 Aug 2022
EPS came in at -$0.81 surpassing the estimated -$0.92 by +11.96%, while revenue for the quarter reached $73.75m , beating expectations by +171.23%.
Earnings released on 5 May 2022
EPS came in at -$1.19 falling short of the estimated -$1.13 by -5.31%, while revenue for the quarter reached $1.69m , missing expectations by -63.92%.
Earnings released on 24 Feb 2022
EPS came in at -$1.01 falling short of the estimated -$0.83 by -21.69%, while revenue for the quarter reached $12.89m , missing expectations by -40.24%.
Earnings released on 4 Nov 2021
EPS came in at -$1.06 falling short of the estimated -$0.91 by -16.48%, while revenue for the quarter reached $2.34m , missing expectations by -84.48%.
Earnings released on 5 Aug 2021
EPS came in at -$0.66 surpassing the estimated -$0.93 by +29.03%, while revenue for the quarter reached $54.02m , beating expectations by +55.06%.
BBIO Stock Performance
Access detailed BBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
